Radioimmunoguided surgery using monoclonal antibody

Radioimmunoguided surgery in colorectal cancer: A 6-year experience with four different technical solutions

“…Ten years after the first experiences with RIGS [2][3][4], this technique still requires further experimental investigation to assess its potential in clinical oncology.…”

“…Martin, Jr. has been using monoclonal antibody (MAb) B72.3 radiolabeled with Iodine-125 (I 125 ) intravenously administered to colorectal cancer patients and then a gamma-detecting probe (GDP) to identify hot spots that express the target antigen [2][3][4]. The rational for this technology was based on satisfactory scintigraphic outcomes.…”

Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs

“…However, the production of such radiolabeled MoAb is not a simple task and indirectly favors the utilization of "regular" agents such as SSA radiopharmaceuticals. In fact, for example, the conjugation of a radionuclide to an antibody may potentially change the specific binding properties of the MoAb itself reducing its affinity and/or avidity for the intended target antigen and thus undermining its clinical efficacy [40][41][42].…”

Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma – implications for radioimmunotherapy

“…The % inj.act kg-' in tumour showed a significant correlation with that in the blood for both groups (P = 0.005 and P = 0.01). There was no significant correlation for either time group between % inj.act kg- ' (Begent et al, 1985;Martin et al, 1988;Begent, 1990). There is great variability in uptake of antibody in individual tumours in patients and the factors influencing this are poorly understood.…”